Long-Term outcomes of Ultra-Hypofractionated 2 Fractions single day HDR Brachytherapy in Localized Prostate Cancer.

[1]  Liying Zhang,et al.  Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter? , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  D. Baltas,et al.  High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up , 2021, Frontiers in Oncology.

[3]  P. Hoskin,et al.  Ultra-fractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy. , 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  G. Viani,et al.  HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis. , 2021, Brachytherapy.

[5]  G. Merrick,et al.  A biochemical definition of cure after brachytherapy for prostate cancer. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Hans T. Chung,et al.  Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  D Baltas,et al.  High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  P. Hoskin,et al.  Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[10]  Hans T. Chung,et al.  High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  E. Alwers,et al.  High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer , 2015, Journal of contemporary brachytherapy.

[12]  M. Ghilezan,et al.  High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: preliminary toxicity data. , 2012, International journal of radiation oncology, biology, physics.

[13]  F. Vicini,et al.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[14]  Cyrus Chargari,et al.  [Which alpha/beta ratio for prostate cancer in 2019?] , 2019, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[15]  M. Keyes,et al.  Long‐Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy , 2018, The Journal of urology.

[16]  W. J. Morris,et al.  Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival. , 2014, International journal of radiation oncology, biology, physics.